Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Cancer Res ; 61(18): 6925-30, 2001 Sep 15.
Article in English | MEDLINE | ID: mdl-11559571

ABSTRACT

A self-deleting retrovirus vector carrying a herpes simplex virus (HSV)-thymidine kinase suicide gene has been developed to selectively kill cancer cells expressing a dysfunctional p53 tumor suppressor protein. When cells containing functional p53 are infected with the virus, the integrated provirus and the HSV-thymidine kinase gene are deleted from the genome by site-specific recombination (Cre/loxP). In contrast, cells without p53 or cells expressing a DNA-binding mutant of p53 retain the provirus and become susceptible to killing by ganciclovir. This strategy provides a new concept for the selective killing of cancer cells that can be adapted to any other dysfunctional transcription factor expressed by different tumors.


Subject(s)
Genetic Therapy/methods , Retroviridae/genetics , Tumor Suppressor Protein p53/deficiency , Animals , Female , Ganciclovir/pharmacokinetics , Ganciclovir/pharmacology , Genetic Vectors/genetics , Humans , Mice , Mice, Nude , Proviruses/genetics , Simplexvirus/enzymology , Simplexvirus/genetics , Thymidine Kinase/genetics , Thymidine Kinase/metabolism , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/physiology , Virus Integration/genetics , Xenograft Model Antitumor Assays
2.
Cancer Res ; 60(20): 5781-8, 2000 Oct 15.
Article in English | MEDLINE | ID: mdl-11059774

ABSTRACT

The consistent presence of the EBV genome in certain tumors offers the potential for novel EBV-directed therapies. Switching the latent form of EBV infection present in most EBV-positive tumor cells into the cytolytic form may be clinically useful because lytic EBV infection leads to host cell destruction, and very few normal cells contain the EBV genome. It would also be therapeutically advantageous to induce expression of EBV-encoded lytic proteins that convert the nucleoside analogues ganciclovir (GCV) and 3'-azido-3'deoxythymidine (AZT) into their active, cytotoxic forms. In this report, we have explored two different approaches for activating the lytic form of EBV infection in tumors. We show that gamma-irradiation at clinically relevant doses induces lytic EBV infection in lymphoblastoid cell lines in vitro as well as in EBV-positive B-cell tumors in SCID mice. In addition, sodium butyrate (given as a single i.p. dose) is effective for activating lytic viral infection in some EBV tumor types in SCID mice. We also examined whether low-dose gamma-irradiation treatment of EBV-positive lymphoblastoid cells in vitro promotes GCV or AZT susceptibility. The combination of radiation with either GCV or AZT induced significantly more cell killing in vitro than either radiation or prodrug treatment alone. Most importantly, we found that the combination of gamma-irradiation and GCV was much more effective in treating EBV-positive lymphoblastoid tumors in SCID mice than either agent alone. Thus, GCV or AZT treatment could potentially enhance the therapeutic efficacy of radiation therapy for EBV-positive lymphomas in patients.


Subject(s)
Butyrates/pharmacology , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/growth & development , Neoplasms, Experimental/virology , Tumor Virus Infections/virology , Virus Activation/drug effects , Virus Activation/radiation effects , Animals , Antiviral Agents/pharmacokinetics , Antiviral Agents/pharmacology , B-Lymphocytes/drug effects , B-Lymphocytes/radiation effects , B-Lymphocytes/virology , Biotransformation , Burkitt Lymphoma/pathology , Burkitt Lymphoma/therapy , Burkitt Lymphoma/virology , Cell Death/drug effects , Cell Death/radiation effects , Cell Line, Transformed , Epstein-Barr Virus Infections/metabolism , Ganciclovir/pharmacokinetics , Ganciclovir/pharmacology , Herpesvirus 4, Human/drug effects , Herpesvirus 4, Human/radiation effects , Humans , Lymphocytes/drug effects , Lymphocytes/radiation effects , Lymphocytes/virology , Mice , Mice, SCID , Neoplasms, Experimental/pathology , Neoplasms, Experimental/therapy , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Stomach Neoplasms/virology , Tumor Virus Infections/metabolism , Xenograft Model Antitumor Assays , Zidovudine/pharmacokinetics , Zidovudine/pharmacology
3.
Cancer Gene Ther ; 7(1): 97-106, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10678362

ABSTRACT

Epstein-Barr virus (EBV)-based gene delivery vectors that preferentially express toxic genes in EBV-infected cells could be used to target EBV-positive tumors for destruction. We have shown previously that the cytosine deaminase (CD) enzyme, which converts the prodrug 5-fluorocytosine (5-FC) into the toxic compound 5-fluorouracil efficiently kills EBV-positive cells in the presence of 5-FC, with a substantial bystander killing effect in vitro and in vivo. To identify the optimal enzyme/prodrug combination for treating EBV-positive lymphomas, we have compared the effectiveness of the CD/5-FC combination with the nitroreductase (NTR)/CB1954 combination for killing EBV-positive B-cell lines. NTR metabolizes CB1954 into an alkylating agent that cross-links DNA. When the CD gene or the NTR gene were transfected into two different EBV-positive B-cell lines in vitro, approximately 90% of cells were killed in a prodrug-dependent manner, although the transfection efficiency was <5%. However, severe combined immunodeficient mouse tumors containing either 30% or 100% of NTR-expressing Burkitt lymphoma (Jijoye) cells were growth inhibited, but not cured, by treatment with intraperitoneal CB1954 (20 mg/kg/day) for 10 days. These results suggest that the NTR/CB1954 combination induces efficient bystander killing of EBV-positive B-cell lines in vitro but may not be as effective as the CD/5-FC combination for treating B-cell lymphomas in vivo.


Subject(s)
Antineoplastic Agents/pharmacology , Aziridines/pharmacology , B-Lymphocytes , Genetic Therapy , Herpesvirus 4, Human/genetics , Lymphoma/therapy , Nitroreductases/genetics , Nucleoside Deaminases/genetics , Animals , Aziridines/administration & dosage , Callithrix , Cytosine Deaminase , Disease Models, Animal , Humans , Lymphoma/genetics , Mice , Mice, SCID , Neoplasm Transplantation , Nitroreductases/administration & dosage , Nitroreductases/metabolism , Nucleoside Deaminases/metabolism , Plasmids/genetics , Prodrugs/therapeutic use , Tumor Cells, Cultured
4.
Cancer Res ; 59(7): 1485-91, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-10197618

ABSTRACT

The consistent presence of EBV genomes in certain tumor types (in particular, AIDS-related central nervous system lymphomas and nasopharyngeal carcinomas) may allow novel, EBV-based targeting strategies. Tumors contain the latent (transforming) form of EBV infection. However, expression of either of the EBV immediate-early proteins, BZLF1 and BRLF1, is sufficient to induce lytic EBV infection, resulting in death of the host cell. We have constructed replication-deficient adenovirus vectors expressing the BZLF1 or BRLF1 immediate-early genes and examined their utility for killing latently infected lymphoma cells in vitro and in vivo. We show that both the BZLF1 and BRLF1 vectors efficiently induce lytic EBV infection in Jijoye cells (an EBV-positive Burkitt lymphoma cell line). Furthermore, lytic EBV infection converts the antiviral drug, ganciclovir (GCV), into a toxic (phosphorylated) form, which inhibits cellular as well as viral DNA polymerase. When Jijoye cells are infected with the BZLF1 or BRLF1 adenovirus vectors in the presence of GCV, viral reactivation is induced, but virus replication is inhibited (thus preventing the release of infectious EBV particles); yet cells are still efficiently killed. Finally, we demonstrate that the BZLF1 and BRLF1 adenovirus vectors induce lytic EBV infection when they are directly inoculated into Jijoye cell tumors grown in severe combined immunodeficiency mice. These results suggest that induction of lytic EBV infection in tumors, in combination with GCV, may be an effective strategy for treating EBV-associated malignancies.


Subject(s)
Adenoviridae/genetics , Burkitt Lymphoma/virology , DNA-Binding Proteins/genetics , Herpesvirus 4, Human/genetics , Immediate-Early Proteins/genetics , Trans-Activators/genetics , Transcription Factors/genetics , Viral Proteins , Animals , Ganciclovir/metabolism , Ganciclovir/pharmacology , Genetic Vectors , Humans , Mice , Mice, SCID , Phosphorylation , Tumor Cells, Cultured , Virus Latency , Virus Replication/drug effects
5.
Hum Gene Ther ; 9(13): 1863-73, 1998 Sep 01.
Article in English | MEDLINE | ID: mdl-9741425

ABSTRACT

A novel shuttle vector, pBH140, has been constructed that allows stable maintenance of large genomic inserts as human artificial episomal chromosomes (HAECs) in mammalian cells. The vector, essentially a hybrid BAC-HAEC, contains an F-based replication system as in a bacterial artificial chromosome (BAC) and the Epstein-Barr virus (EBV) latent origin of replication system, oriP, for replication in human cells. A 185-kb DNA insert containing the entire human beta-globin locus, including its locus control region (LCR), was retrofitted into this vector. The resulting beta-globin BAC-HAEC clone, p148BH, was transfected into human cells and analyzed for episomal maintenance and expression of the beta-globin gene. FISH revealed an association of the vector with different human chromosomes but no integration. The beta-globin BAC-HAECs were present at an average copy number of 11-15 per nucleus in the stably transformed human cells. After 1 year of continuous in vitro cultivation, the HAECs persisted as structurally intact 200-kb episomes. While no beta-globin transcription could be detected in the parental D98/Raji cells, correctly spliced RT-PCR products were produced at significant levels in long-term cultures of the BAC-HAEC-transduced cells. The wide availability of BAC and PAC libraries, the ease in manipulating cloned DNA in bacteria, and the episomal stability of the pBH140 vector make this system ideal for studies on gene expression and other genomic functions in human cells. The potential significance of large, functionally active episomes for gene therapy is discussed.


Subject(s)
Cloning, Molecular/methods , Genetic Vectors/genetics , Globins/genetics , Plasmids/genetics , Transfection , Cell Line, Transformed , Chromosomes, Bacterial/genetics , Chromosomes, Human , DNA Replication , Epstein-Barr Virus Nuclear Antigens , Extrachromosomal Inheritance , Gene Dosage , Gene Expression Regulation , Humans , Replication Origin/genetics , Time Factors , Transcriptional Activation
6.
Hum Gene Ther ; 9(8): 1131-41, 1998 May 20.
Article in English | MEDLINE | ID: mdl-9625252

ABSTRACT

B cell lymphomas in immunocompromised patients frequently contain the Epstein-Barr virus (EBV) genome (MacMahon et al, 1991), suggesting that gene therapy strategies that target EBV-positive cells for destruction might be useful for the therapy of such tumors. We have previously shown that stable expression of the cytosine deaminase (CD) gene in EBV-positive lymphoblastoid cell lines induces cell killing in the presence of the prodrug 5-fluorocytosine, with a substantial bystander killing effect (Rogers et al., 1996). To promote specific killing of EBV-positive tumor cells, we have constructed two different EBV-based vectors containing the cytosine deaminase gene. The first vector (OriP-CD), which contains the intact EBV oriP enhancer/replication element, replicates as an episome specifically in EBV-positive cells and likewise enhances transcription in an EBV-specific manner. The OriP-CD vector cannot be packaged or spread from cell to cell. The second vector (OriLyt-CD) contains the EBV lytic origin of replication (oriLyt), the EBV packaging sequences (located in the viral termini), the oriP enhancer element (but not the complete replication origin), and the EBV BZLF1 gene (which induces expression of the EBV proteins required for replication of oriLyt). The OriLyt-CD vector is replicated through the oriLyt origin specifically in EBV-positive cells and packaged as an EBV pseudovirion. The packaged oriLyt-CD virion can subsequently infect cells containing the EBV receptor, CD21, and initiate another round of replication in EBV-positive cells. Here we demonstrate that each of these two different EBV-based gene therapy strategies induces specific killing of EBV-positive B cells in vitro (in the presence of 5-FC). The advantages and disadvantages of each strategy are discussed.


Subject(s)
Genetic Therapy , Genetic Vectors , Genome, Viral , Herpesvirus 4, Human/isolation & purification , Lymphoma, B-Cell/therapy , Tumor Virus Infections/therapy , Animals , Cell Death/drug effects , Cell Line , Herpesvirus 4, Human/genetics , Humans , Immunocompromised Host , Lac Operon , Lymphoma, B-Cell/virology , Tumor Cells, Cultured , Virion/genetics
7.
Cancer Res ; 54(16): 4294-8, 1994 Aug 15.
Article in English | MEDLINE | ID: mdl-8044774

ABSTRACT

An allelotype analysis of endometrial carcinoma was undertaken to identify chromosomal loci that are relevant to this tumor type. A total of 70 highly polymorphic microsatellite markers, distributed among all nonacrocentric chromosome arms, were examined for evidence of loss of heterozygosity or allelic imbalance in DNA samples from matched normal and tumor tissues. An average of 21 informative tumor cases were obtained for each marker. Allelic deletions or imbalance were observed on 31 of 41 chromosome arms with no marker showing an allelic loss ratio of greater than 33%. Those chromosome arms most frequently involved were 3p, 8p, 9p, 14q, 16q and 18q. There was a strong correlation between loss of heterozygosity on chromosome 14q and death from disease. These data indicate that the molecular genetic character of endometrial carcinoma is complex and that a relatively large number of different chromosomal loci are likely to play a role in the etiology and progression of this tumor type.


Subject(s)
Endometrial Neoplasms/genetics , Gene Deletion , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 16 , Chromosomes, Human, Pair 18 , Chromosomes, Human, Pair 3 , Chromosomes, Human, Pair 8 , Chromosomes, Human, Pair 9 , Endometrial Neoplasms/pathology , Female , Genetic Markers , Genotype , Humans , Prognosis
8.
Mol Carcinog ; 2(2): 72-80, 1989.
Article in English | MEDLINE | ID: mdl-2548528

ABSTRACT

Mapping analysis of the nucleosomal organization of integrated human papillomavirus type 18 (HPV18) DNA in HeLa cells reveals a very prominent nuclease-hypersensitive site within the viral noncoding regulatory region that harbors transcriptional control sequences and coincides with most of the 5' ends of the cytoplasmic early mRNAs. Moreover, it is shown that the conserved coamplified 5' cellular flank, common to all HPV18 copies in HeLa cells and located close to the virus-cell integration site, also contains several distinct hypersensitive sites, accessible not only to DNase I but also to restriction enzymes. Nuclear run-on analysis in isolated HeLa nuclei demonstrates the occurrence of nascent transcripts covering the cellular flank (the late and the viral noncoding regulatory region), indicating that a cellular promoter, marked by the hypersensitive sites, cooperates with the viral control region in generating the HPV18 transcripts. Cycloheximide treatment of HeLa cells results in a reduction of the cytoplasmic steady-state level of the 3.5-kb mRNA corresponding to the viral E6, E7, and parts of the E1 open reading frames (ORFs), whereas the expression of the 1.6-kb transcript corresponding only to the E6 and E7 ORFs is not influenced. Nuclear run-on analysis carried out after the cycloheximide chase reveals that the distribution of nascent transcripts spanning the viral E6, E7, and parts of the E1 region is substantially decreased. In contrast to this finding, an even, pronounced increase of the elongation rate of those transcripts, which cover the cellular flank, the late and the viral noncoding regulatory region was noted indicating a different involvement of regulatory factors in the activity of both promoters.


Subject(s)
Chromatin , DNA, Viral/genetics , Papillomaviridae/genetics , Regulatory Sequences, Nucleic Acid , Transcription, Genetic , Blotting, Southern , Cycloheximide/pharmacology , DNA Probes , DNA, Viral/drug effects , Deoxyribonuclease I , Genes, Viral , HeLa Cells , Humans , RNA, Nuclear/biosynthesis , Restriction Mapping , Transcription, Genetic/drug effects
9.
Hum Genet ; 79(3): 260-4, 1988 Jul.
Article in English | MEDLINE | ID: mdl-2456982

ABSTRACT

Deficiency in hepatic tyrosine aminotransferase (TAT) causes tyrosinemia type II, an autosomal recessively inherited disorder. Using a TAT cosmid clone, we have identified an MspI restriction fragment length polymorphism (RFLP) 5' to the TAT gene, with allele frequencies of 0.63 and 0.37. Analysis of the cloned maternal and paternal TAT alleles from a patient with tyrosinemia type II led to the identification of a HaeIII RFLP at the 3' end of the TAT gene, with allele frequencies of 0.94 and 0.06. The two RFLPs are 27 kb apart and in no allelic association. From haplotype frequencies, a polymorphism information content (PIC) value of 0.44 was obtained. The two RFLPs have allowed the unambiguous identification of the mutant TAT alleles in the patient's pedigree by haplotype analysis.


Subject(s)
Amino Acid Metabolism, Inborn Errors/genetics , Genes , Haplotypes , Polymorphism, Genetic , Polymorphism, Restriction Fragment Length , Tyrosine Transaminase/genetics , Tyrosine/metabolism , Amino Acid Metabolism, Inborn Errors/enzymology , Cloning, Molecular , Cosmids , DNA Restriction Enzymes , Deoxyribonuclease HpaII , Exons , Female , Humans , Male , Pedigree , Phenotype , Reference Values
10.
Hum Genet ; 77(4): 352-8, 1987 Dec.
Article in English | MEDLINE | ID: mdl-2891604

ABSTRACT

Tyrosinemia II is an autosomal-recessively inherited condition caused by deficiency in the liver-specific enzyme tyrosine aminotransferase (TAT; EC 2.6.1.5). We have restudied a patient with typical symptoms of tyrosinemia II who in addition suffers from multiple congenital anomalies including severe mental retardation. Southern blot analysis using a human TAT cDNA probe revealed a complete deletion of both TAT alleles in the patient. Molecular and cytogenetic analysis of the patient and his family showed one deletion to be maternally inherited, extending over at least 27 kb and including the complete TAT structural gene, whereas loss of the second TAT allele results from a small de novo interstitial deletion, del 16 (pter----q22.1::q22.3----qter), in the paternally inherited chromosome 16. Three additional loci previously assigned to 16q22 were studied in our patient: haptoglobin (HP), lecithin: cholesterol acyltransferase (LCAT), and the metallothionein gene cluster MT1,MT2. Of these three markers, only the HP locus was found to be codeleted with the TAT locus on the del(16) chromosome.


Subject(s)
Amino Acid Metabolism, Inborn Errors/genetics , Chromosome Deletion , Chromosomes, Human, Pair 16 , Tyrosine Transaminase/deficiency , Tyrosine/blood , Alleles , Child, Preschool , Chromosome Banding , Chromosome Mapping , Humans , Male , Pedigree , Polymorphism, Restriction Fragment Length , Tyrosine Transaminase/genetics
11.
Genomics ; 1(4): 313-9, 1987 Dec.
Article in English | MEDLINE | ID: mdl-2896626

ABSTRACT

The loci for haptoglobin (HP) and tyrosine aminotransferase (TAT) are known to reside at 16q22. Chymotrypsinogen B (CTRB), which is syntenic with TAT and HP on mouse chromosome 8, has also been assigned to human chromosome 16 but has not been mapped regionally. A linkage analysis was carried out in 13 informative families using RFLPs for these three markers. For CTRB, two TaqI RFLPs with a polymorphism information content of 0.60 derived from haplotype frequencies are described. The most likely order of loci, deduced from triple informative crosses, and their map distances, obtained by pair-wise linkage analysis, are HP-7 cM-TAT-9 cM-CTRB. By pulsed-field gel electrophoresis, a physical map covering more than 2000 kb was constructed. A maximum physical distance of about 700 kb was obtained for HP and TAT, which contrasts with the genetic distance of 7 cM (approximate confidence limits 2-18 cM). CTRB is at least 800 kb away from these two markers.


Subject(s)
Chromosomes, Human, Pair 16 , Chymotrypsinogen/genetics , Haptoglobins/genetics , Tyrosine Transaminase/genetics , Amino Acid Metabolism, Inborn Errors/genetics , Chromosome Mapping , Chromosomes, Human, Pair 16/ultrastructure , Female , Genetic Linkage , Humans , Male , Polymorphism, Restriction Fragment Length
SELECTION OF CITATIONS
SEARCH DETAIL
...